Glaxo Specialty (Medical Benefit) 49401010201 - … | USA MedPremium
Benlysta® Belimumab 400 mg Injection - Treatment for Systemic Lupus Erythematosus (SLE) and Lupus Nephritis
USAMP#28944529SKU: 49401010201Benlysta®
License Required
Product Spotlight
Benlysta® (Belimumab) is a targeted B-lymphocyte stimulator (BLyS)-specific inhibitor, designed to treat autoantibody-positive systemic lupus erythematosus (SLE) in patients 5 years and older, alongside standard therapy.
It is also approved for the management of adult patients with active lupus nephritis, as part of a comprehensive treatment plan.
Benlysta® is a sterile, preservative-free injection, ensuring safety and efficacy for immune system modulation.
Designed for single-use in a 20 mL vial, this 400 mg formulation requires refrigeration to maintain its stability and potency.
